(HLF) Herbalife Nutrition - Overview
Sector: Consumer Defensive | Industry: Packaged Foods | Exchange: NYSE (USA) | Market Cap: 1.289m USD | Total Return: 58.6% in 12m
Avg Turnover: 18.6M
EPS Trend: -52.1%
Qual. Beats: 0
Rev. Trend: -14.2%
Qual. Beats: 0
Warnings
Altman Z'' 0.84 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Herbalife Ltd. (HLF) is a global health and wellness company that develops and sells weight management, targeted nutrition, and personal care products. Its portfolio includes meal replacement shakes, dietary supplements, and fitness-oriented functional beverages distributed across North America, Europe, China, and the Asia Pacific.
The company operates under a multi-level marketing (MLM) business model, utilizing a network of independent sales representatives and service providers rather than traditional retail channels. This model shifts the primary costs of distribution and customer acquisition to independent contractors, a common structure within the Personal Care Products sub-industry for brands focusing on direct-to-consumer engagement.
You may find further insights on the companys valuation metrics by exploring ValueRay. Founded in 1980 and headquartered in Los Angeles, the firm underwent a corporate name change from Herbalife Nutrition Ltd. to Herbalife Ltd. in April 2023 to reflect its broader wellness positioning.
- Independent distributor recruitment and retention rates drive global sales volume growth
- Regulatory scrutiny of multi-level marketing structures impacts long-term valuation multiples
- Currency fluctuations in emerging markets significantly affect reported net revenue and margins
- Consumer demand for weight management products shifts toward GLP-1 pharmaceutical alternatives
- High debt leverage and interest expenses constrain free cash flow for share buybacks
| Net Income: 239.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 6.88 > 1.0 |
| NWC/Revenue: 4.48% < 20% (prev -0.71%; Δ 5.19% < -1%) |
| CFO/TA 0.16 > 3% & CFO 446.9m > Net Income 239.8m |
| Net Debt (1.73b) to EBITDA (593.3m): 2.92 < 3 |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (108.4m) vs 12m ago 6.07% < -2% |
| Gross Margin: 75.93% > 18% (prev 0.78%; Δ 7.51k% > 0.5%) |
| Asset Turnover: 184.7% > 50% (prev 184.4%; Δ 0.23% > 0%) |
| Interest Coverage Ratio: 2.26 > 6 (EBITDA TTM 593.3m / Interest Expense TTM 209.3m) |
| A: 0.08 (Total Current Assets 1.25b - Total Current Liabilities 1.02b) / Total Assets 2.88b |
| B: -0.18 (Retained Earnings -517.8m / Total Assets 2.88b) |
| C: 0.17 (EBIT TTM 473.4m / Avg Total Assets 2.78b) |
| D: -0.23 (Book Value of Equity -775.5m / Total Liabilities 3.31b) |
| Altman-Z'' = 0.84 = B |
| DSRI: 1.13 (Receivables 106.0m/90.1m, Revenue 5.13b/4.95b) |
| GMI: 1.03 (GM 75.93% / 78.09%) |
| AQI: 1.00 (AQ_t 0.36 / AQ_t-1 0.36) |
| SGI: 1.04 (Revenue 5.13b / 4.95b) |
| TATA: -0.07 (NI 239.8m - CFO 446.9m) / TA 2.88b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 12.12 with a total of 1,074,191 shares traded.
Over the past week, the price has changed by -3.73%,
over one month by -26.37%,
over three months by -37.14% and
over the past year by +58.64%.
Herbalife Nutrition has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold HLF.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 18 | 48.5% |
P/E Trailing = 5.4518
P/E Forward = 4.7348
P/S = 0.251
P/B = 31.1876
P/EG = 0.6145
Revenue TTM = 5.13b USD
EBIT TTM = 473.4m USD
EBITDA TTM = 593.3m USD
Long Term Debt = 1.98b USD (from longTermDebt, last quarter)
Short Term Debt = 9.20m USD (from shortTermDebt, last quarter)
Debt = 2.18b USD (corrected: LT Debt 1.98b + ST Debt 9.20m) + Leases 191.1m
Net Debt = 1.73b USD (calculated: Debt 2.18b - CCE 451.2m)
Enterprise Value = 3.02b USD (1.29b + Debt 2.18b - CCE 451.2m)
Interest Coverage Ratio = 2.26 (Ebit TTM 473.4m / Interest Expense TTM 209.3m)
EV/FCF = 8.08x (Enterprise Value 3.02b / FCF TTM 373.9m)
FCF Yield = 12.38% (FCF TTM 373.9m / Enterprise Value 3.02b)
FCF Margin = 7.28% (FCF TTM 373.9m / Revenue TTM 5.13b)
Net Margin = 4.67% (Net Income TTM 239.8m / Revenue TTM 5.13b)
Gross Margin = 75.93% ((Revenue TTM 5.13b - Cost of Revenue TTM 1.24b) / Revenue TTM)
Gross Margin QoQ = 75.64% (prev 75.12%)
Tobins Q-Ratio = 1.05 (Enterprise Value 3.02b / Total Assets 2.88b)
Interest Expense / Debt = 9.59% (Interest Expense 209.3m / Debt 2.18b)
Taxrate = 33.19% (30.4m / 91.6m)
NOPAT = 316.3m (EBIT 473.4m * (1 - 33.19%))
Current Ratio = 1.23 (Total Current Assets 1.25b / Total Current Liabilities 1.02b)
Debt / Equity = -4.94 (negative equity) (Debt 2.18b / totalStockholderEquity, last quarter -441.5m)
Debt / EBITDA = 2.92 (Net Debt 1.73b / EBITDA 593.3m)
Debt / FCF = 4.63 (Net Debt 1.73b / FCF TTM 373.9m)
Total Stockholder Equity = -557.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.63% (Net Income 239.8m / Total Assets 2.88b)
RoE = -607.5% (negative equity) (Net Income TTM 239.8m / Total Stockholder Equity -39.5m)
RoCE = 24.37% (EBIT 473.4m / Capital Employed (Equity -39.5m + L.T.Debt 1.98b))
RoIC = 16.98% (NOPAT 316.3m / Invested Capital 1.86b)
WACC = 7.58% (E(1.29b)/V(3.47b) * Re(9.57%) + D(2.18b)/V(3.47b) * Rd(9.59%) * (1-Tc(0.33)))
Discount Rate = 9.57% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 3.51%
[DCF] Terminal Value 77.97% ; FCFF base≈290.1m ; Y1≈332.6m ; Y5≈489.4m
[DCF] Fair Price = 54.35 (EV 7.37b - Net Debt 1.73b = Equity 5.63b / Shares 103.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -52.11 | EPS CAGR: -5.73% | SUE: -0.35 | # QB: 0
Revenue Correlation: -14.21 | Revenue CAGR: -0.18% | SUE: 0.12 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.63 | Chg30d=-3.15% | Revisions=-14% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.71 | Chg30d=+7.22% | Revisions=+43% | Analysts=3
EPS current Year (2026-12-31): EPS=2.67 | Chg30d=+7.41% | Revisions=+33% | GrowthEPS=+25.8% | GrowthRev=+4.2%
EPS next Year (2027-12-31): EPS=3.14 | Chg30d=+5.58% | Revisions=+14% | GrowthEPS=+17.5% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: +43%